Jupiter Topco’s Zevra Therapeutics ZVRA Stock Holding History

Jupiter Topco’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.8M	Buy	+613,403	New	+$6.82M	﹤0.01%	843

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Jupiter Topco's ZVRA Position: Q2 2026 in Review

Jupiter Topco opened a new position in Zevra Therapeutics (ZVRA) in Q2 2026: 613,403 shares worth $8.8M. The stake represents ﹤0.01% of the portfolio and ranks #843 among its holdings.

144 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Jupiter Topco held 613,403 shares of Zevra Therapeutics worth $8.8M as of Q2 2026.
Zevra Therapeutics was a new Jupiter Topco position in Q2 2026.
Zevra Therapeutics made up ﹤0.01% of Jupiter Topco's portfolio in Q2 2026, its #843 holding.
144 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Jupiter Topco's 13F filing for Q2 2026, filed 14 Aug 2026.